OMass Therapeutics partners with Genentech to advance innovative treatments for inflammatory bowel disease, leveraging their ...

Roche’s Genentech unit has handed over $20 million in upfront cash for the license to Omass Therapeutics’ preclinical inflammatory bowel disease (IBD) program. | Roche’s Genentech unit has handed over ...

Collaboration leverages OMass’ OdyssionTM platform for the continued development of oral small molecules against a first-in-class target in ...

Oxford, UK-based biotech OMass Therapeutics today announced it has entered into an exclusive collaboration and license ...

The OMass partnership will boost Roche’s strategy in inflammatory bowel diseases, currently led by afimkibart, an anti-TL1A ...

UK biotech OMass Therapeutics has revealed its first major pharma partnership, with Roche's Genentech unit paying $20 million ...

A drug discovery company based in Oxford, UK, spun out of Oxford University.

OMass Therapeutics is a biotechnology company discovering medicines against highly- validated target ecosystems, such as membrane proteins or intracellular complexes.

PRESS RELEASE OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases Financing led by new investors, GV, Northpond Ventures and ...

OMass is advancing a pipeline of small molecule therapeutics in rare diseases and immunological conditions. Its lead program is a best-in-class MC2 (melanocortin-2) receptor antagonist for the ...